Multicarrier Nanoplatforms for Precise Targeting of Cellular Energy Centers in Ischemic Heart Disease Therapy
ACS Nano Medicine · 11.02.2026 · 1 (1) · 193-222
DOI: 10.1021/acsnanomed.5c00057 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 15.10.2025. Verfasst von Wenjia Zhang und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 178 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide Mitochondria, as the core organelle of cellular energy metabolism and fate regulation, not only maintain the balance between myocardial reactive oxygen species ROS and energy metabolism but also regulate key pathological processes such as apoptosis, calcium homeostasis and mPTP opening, which is an important target for IHD treatment. With the aging of the population and the increase of risk factors (such as hypertension, diabetes, obesity), the incidence and prevalence of IHD are still increasing. Although interventional therapy and surgery have achieved certain results, they still face challenges such as reperfusion injury and poor long-term prognosis. In recent years, nanomedicine has shown significant potential for restoring energy supply and breaking the vicious cycle of oxidative stress by virtue of its precise targeting and regulation ability, especially in mitochondrial targeted intervention. Through strategies such as specific ligand recognition, pathological microenvironment responsive drug release, and biomimetic modification, functionalized nanosystems can accurately deliver therapeutic drugs to diseased mitochondria, thereby effectively interfering with the progress of IHD. However, the existing research has not systematically reviewed and discussed the therapeutic strategies and molecular mechanisms of mitochondrial targeted drugs, which is difficult to meet the urgent needs of scientific research and clinical practice. This paper focuses on the core role of mitochondria in IHD, analyzes the design strategy and mechanism of mitochondrial targeted nanomedicine, summarizes the latest research progress of nanocarriers in this field, and looks forward to the application of artificial intelligence in the development and optimization of nanomedicine, to provide a comprehensive perspective and theoretical basis for the precision and clinical transformation of IHD treatment.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, W., Xiao, H., Ma, Y., Lyu, X., Li, K., He, L., & Liu, S. (2026). Multicarrier Nanoplatforms for Precise Targeting of Cellular Energy Centers in Ischemic Heart Disease Therapy. ACS Nano Medicine, 1(1), 193-222. https://doi.org/10.1021/acsnanomed.5c00057
Vancouver
Zhang W, Xiao H, Ma Y, Lyu X, Li K, He L, et al. Multicarrier Nanoplatforms for Precise Targeting of Cellular Energy Centers in Ischemic Heart Disease Therapy. ACS Nano Medicine. 2026;1(1):193-222. doi:10.1021/acsnanomed.5c00057
BibTeX
@article{Zhang2026,
author = {Zhang, Wenjia and Xiao, Hui and Ma, Yixue and Lyu, Xingru and Li, Kai and He, Liangcan and Liu, Shaoqin},
title = {Multicarrier Nanoplatforms for Precise Targeting of Cellular Energy Centers in Ischemic Heart Disease Therapy},
journal = {ACS Nano Medicine},
year = {2026},
volume = {1},
number = {1},
pages = {193--222},
doi = {10.1021/acsnanomed.5c00057}
}
EUVIMED